

# Accepted Manuscript

Cell-free plasma DNA-guided treatment with osimertinib in patients with advanced *EGFR*-mutated NSCLC

Anna Buder, MSc, Maximilian J. Hochmair, MD, Sophia Schwab, Tatjana Bundalo, MD, Peter Schenk, MD, Peter Errhalt, MD, Romana E. Mikes, MD, Gudrun Absenger, MD, Kurt Patocka, MD, Bernhard Baumgartner, MD, Ulrike Setinek, MD, Otto C. Burghuber, MD, Helmut Prosch, MD, Robert Pirker, MD, Martin Filipits, PhD

PII: S1556-0864(18)30167-9

DOI: [10.1016/j.jtho.2018.02.014](https://doi.org/10.1016/j.jtho.2018.02.014)

Reference: JTHO 880

To appear in: *Journal of Thoracic Oncology*

Received Date: 25 July 2017

Revised Date: 4 January 2018

Accepted Date: 24 February 2018

Please cite this article as: Buder A, Hochmair MJ, Schwab S, Bundalo T, Schenk P, Errhalt P, Mikes RE, Absenger G, Patocka K, Baumgartner B, Setinek U, Burghuber OC, Prosch H, Pirker R, Filipits M, Cell-free plasma DNA-guided treatment with osimertinib in patients with advanced *EGFR*-mutated NSCLC, *Journal of Thoracic Oncology* (2018), doi: 10.1016/j.jtho.2018.02.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Cell-free plasma DNA-guided treatment with osimertinib in patients with  
advanced *EGFR*-mutated NSCLC**

Anna Buder MSc<sup>1\*</sup>, Maximilian J. Hochmair MD<sup>4\*</sup>, Sophia Schwab<sup>4</sup>, Tatjana Bundalo MD<sup>5</sup>,  
Peter Schenk MD<sup>5</sup>, Peter Errhalt MD<sup>6</sup>, Romana E. Mikes MD<sup>7</sup>, Gudrun Absenger MD<sup>8</sup>, Kurt  
Patocka MD<sup>9</sup>, Bernhard Baumgartner MD<sup>10</sup>, Ulrike Setinek MD<sup>4</sup>, Otto C. Burghuber MD<sup>4</sup>,  
Helmut Prosch MD<sup>3</sup>, Robert Pirker MD<sup>2</sup>, Martin Filipits PhD<sup>1</sup>

\*AB and MJH contributed equally to this work.

<sup>1</sup>Institute of Cancer Research and <sup>2</sup>Division of Oncology, Department of Medicine I,  
<sup>3</sup>Department of Radiology, Comprehensive Cancer Center, Medical University of Vienna,  
Vienna; <sup>4</sup>Department of Respiratory and Critical Care Medicine, and Ludwig Boltzmann  
Institute of COPD and Respiratory Epidemiology, Otto Wagner Hospital, Vienna;  
<sup>5</sup>Department of Pneumology, LKH Hohegg, Hohegg; <sup>6</sup>Department of Pneumology,  
University Hospital Krems, Krems; <sup>7</sup>Department of Pulmonary Medicine, University Clinic  
Salzburg, Salzburg; <sup>8</sup>Division of Clinical Oncology, Department of Medicine, Medical  
University of Graz, Graz; <sup>9</sup>Department of Pneumology, Hietzing Hospital, Vienna;  
<sup>10</sup>Department of Pneumology, Vöcklabruck Hospital, Vöcklabruck, Austria.

**Correspondence to:**

Martin Filipits, PhD

Associate Professor

Institute of Cancer Research, Department of Medicine I  
Comprehensive Cancer Center, Medical University of Vienna  
Borschkegasse 8a, 1090 Vienna, Austria

Phone: +43 1 40160 57528, e-mail: martin.filipits@meduniwien.ac.at

**Running head:** Analyses of cell-free plasma DNA in advanced NSCLC

**Funding:** The study was funded by AstraZeneca

Download English Version:

<https://daneshyari.com/en/article/8787615>

Download Persian Version:

<https://daneshyari.com/article/8787615>

[Daneshyari.com](https://daneshyari.com)